Benzinga Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes. read more
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes. read more